Data from a phase 1b/2a trial have raised doubts about whether Wave Life Sciences’ Huntington’s disease drug can compete with Roche and Ionis’ rival candidate. The results wiped 50% off Wave’s share ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results